Resources Repository
-
Resource PortalWeb Portal, Teaching Resource 2024National Academies of Sciences, Engineering, and Medicine
The National Academies of Sciences, Engineering, and Medicine, founded in 1863, has a mission to provide …
The National Academies of Sciences, Engineering, and Medicine, founded in 1863, has a mission to provide nonpartisan, objective guidance for decision makers on policy challenges in the context of science, engineering, and medicine. NAS reports and convening activities have a wide range of impacts on policy and practice. They guide the development of federal laws and regulations, improve the effectiveness of government programs, shape the direction of research fields, and inform public knowledge and dialogue about…
Cost-Effectiveness Analysis | Risk Analysis | North America | Global | Global Governance | Child/Nutrition | Infectious Diseases | Priority Setting/Ethics | Health Outcomes | Evidence Synthesis | Technology Assessment | Maternal/Reproductive Health | Chronic Disease/Risk | Injuries/Accidents | Social Determinants | Health Systems | Climate/Environment | Energy/Engineering | Education/Labor | Food/Agriculture | Health/Medicine | Military/Defense | Science/Technology | High School | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Policy Translation -
ArticlePublication 2017Estimated Economic Impact of Vaccinations in 73 LMIC, 2001-2020
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 …
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. The authors used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In…
Cost-Effectiveness Analysis | Dynamic Transmission | Asia & Pacific | Middle East & North Africa | Child/Nutrition | Infectious Diseases | Health Outcomes | State-Transition | Microsimulation | Health Systems | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Latin America & Caribbean -
BookPublication 1980Clinical Decision Analysis
This text was conceived and developed in the Harvard T.H. Chan School of Public Health …
This text was conceived and developed in the Harvard T.H. Chan School of Public Health at the Center for the Analysis of Health Practices. The book had its origins in a set of classroom materials developed during the academic year 1974-75 for an elective course in medical decision making at the Harvard Medical School. In this book students are shown how to structure clinical decision problems, how to systematically formulate the intertwining roles of diagnosis and treatment, how to…
Cost-Effectiveness Analysis | Decision Analysis | North America | Global | Child/Nutrition | Infectious Diseases | Probability/Bayes | Preferences/Values | Costing Methods | Health Outcomes | Test Performance | Value of Information | State-Transition | Chronic Disease/Risk | Economics/Finance | Health/Medicine | Europe | Graduate | Doctoral | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
ArticlePublication 2018Equity Impact Vaccines May Have on Averting Deaths and Medical Impoverishment
In this analysis, authors estimated the number of deaths averted and the number of cases …
In this analysis, authors estimated the number of deaths averted and the number of cases of medical impoverishment averted of ten antigens and their corresponding vaccines across income quintiles for forty-one low- and middle-income countries. The study found that vaccines administered between 2016 and 2030 would prevent 36 million deaths. Vaccines will have the greatest impact on reducing cases of poverty caused by hepatitis B, helping an estimated 14 million people avoid medical impoverishment. An…
Cost-Effectiveness Analysis | Asia & Pacific | Middle East & North Africa | Global Governance | Child/Nutrition | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Health Outcomes | Mathematical Models | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa -
Resource PackWeb Portal, Teaching Resource 2017Resource Pack: Valuing Vaccines and GAVI
This resource pack on valuing vaccines and GAVI was curated by the Center for Health …
This resource pack on valuing vaccines and GAVI was curated by the Center for Health Decision Science to showcase existing information and analyses to motivate students, educators and others to pursue new applications of decision science methods to the public health challenge of vaccine preventable illnesses.
Cost-Effectiveness Analysis | Dynamic Transmission | Global | Global Governance | Child/Nutrition | Infectious Diseases | Preferences/Values | Priority Setting/Ethics | Costing Methods | Mathematical Models | Calibration/Validation | Benefit-Cost Analysis | Health Systems | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Policy Translation | Quantitative Literacy -
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Cost-Effectiveness Analysis | Dynamic Transmission | Asia & Pacific | Global Governance | Child/Nutrition | Infectious Diseases | Mathematical Models | Health Systems | Climate/Environment | Economics/Finance | Health/Medicine | Latin America & Caribbean -
ArticleWeb Portal 2017PLoS Collection: Prevention, Diagnosis and Treatment of Sexually Transmitted Infections
Globally, the World Health Organization (WHO) estimates that more than one million new sexually transmitted …
Globally, the World Health Organization (WHO) estimates that more than one million new sexually transmitted infections (STIs) occur each day, incurring a very substantial burden of morbidity, mortality and additional infections. The pathogens responsible include bacteria, parasites and viruses, and intensive research is needed to address the substantial barriers to diagnosis and treatment of STIs, and the behavioral challenges of prevention. This PLOS collection, published in collaboration with WHO, focuses on global policy and systems…
Cost-Effectiveness Analysis | Dynamic Transmission | Asia & Pacific | Middle East & North Africa | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Mathematical Models | Health Systems | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Latin America & Caribbean -
OrganizationWeb Portal 2024PATH
PATH is an international nonprofit organization that has been translating ideas into health solutions for …
PATH is an international nonprofit organization that has been translating ideas into health solutions for 40 years, with a focus on child survival, maternal and reproductive health, and infectious diseases. PATH mobilizes partners around the world in order to take innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. PATH takes a multidimensional approach to solving health challenges, with work spanning five platforms: Vaccines to give children a…
Cost-Effectiveness Analysis | Asia & Pacific | Global | Child/Nutrition | Infectious Diseases | Costing Methods | Health Outcomes | Technology Assessment | Maternal/Reproductive Health | Social Determinants | Health Systems | Health/Medicine | Sub-Saharan Africa -
OrganizationWeb Portal 2024Agency for Healthcare Research and Quality (AHRQ)
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for …
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for research on health care quality, costs, outcomes and patient safety. AHRQ is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. The agency is home to research centers that specialize in major areas of health care research, including: clinical practice…
Cost-Effectiveness Analysis | Decision Analysis | North America | Child/Nutrition | Infectious Diseases | Costing Methods | Health Outcomes | Test Performance | Technology Assessment | Maternal/Reproductive Health | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | Science/Technology